Immunotherapy strongly improved OS (hazard ratio (HR), 0.73; 95% confidence interval (CI), 0.62–0.85; 5-year OS rates, 18% vs. 11%), regardless of tumor PD-L1 expression or histology or presence of baseline brain metastases. Here, CD274 is linked to neoplasm.